Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer
Completed
- Conditions
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Registration Number
- NCT01934478
- Lead Sponsor
- Qingdao Central Hospital
- Brief Summary
Based on fundamental study （in Vitro and in Vivo, Pro. Jianjian Li）， Her2 expression would be changed from negative to positive by cancer irradiation with liner-accelerator at dose 6GY or up. The propose of this study is to reveal the irradiation result on Her2 expression in human breast cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 5
Inclusion Criteria
- histological confirmed advanced breast cancer
- cancer sample can be obtained by fine needle biopsy
- IHC and FISH confirmed Her2 negative
- radiotherapy indication for local residual cancer
Exclusion Criteria
- no radiotherapy indication
- patient refuse
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Her2 changes during radiotherapy every week up to 6 weeks biopsy is obtained by fine needle biopsy，Her2 is checked by Immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH).
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Qingdao Central Hospital, Qingdao Cancer Hospital
🇨🇳Qingdao, Shandong, China